Improving treatment effectiveness for advanced prostate cancer
Official title: Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
Funded at University of California Los Angeles · NIH-10886513 · Data updated 2026-11-12
This study is looking at how to make a special cancer treatment work better for men with advanced prostate cancer by understanding the genes and immune responses of their tumors, so they can improve results and help prevent the cancer from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 12, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $567,087 |
| NIH project number | 5R01CA279094-02 |
| Project ID | NIH-10886513 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who are undergoing or considering PSMA-RPT.
✕Less likely to help
Patients with early-stage prostate cancer or those not eligible for PSMA-RPT may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of prostate-specific membrane antigen-targeted radiopharmaceutical therapy (PSMA-RPT) for patients with metastatic castration-resistant prostate cancer (mCRPC). The team aims to understand the genetic and molecular factors that influence how tumors respond to this therapy. By conducting detailed studies on tumor samples and exploring the immune response, they hope to identify ways to improve patient outcomes and reduce the chances of relapse after treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in enhancing cancer therapies through similar genetic and immunological approaches, indicating potential for success in this area.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Czernin, Johannes — University of California Los Angeles
- Study coordinator: Czernin, Johannes
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.